Author: James Love
as PDF.WIPO Marrakesh Treaty for the blind to come into force September 30, 2016, following ratification by Canada
On June 30, 2016, the WIPO Marrakesh Treaty to Facilitate Access to Published Works for Persons Who Are Blind, Visually Impaired or Otherwise Print Disabled received its 20th ratification, from Canada, and this will bring the Treaty into force September 30, 2016. The WIPO announcement was here. WIPO Director General Francis Gurry made a statement about the Marrakesh Treaty’s imminent entry into force in the video below:
US Chamber of Commerce defends Swiss drug company charging excessive prices in Colombia
|
| David Hirschmann, US Chamber, claims efforts to curb high prices for cancer drugs are “a destructive course.” |
The US Chamber of Commerce might consider renaming itself the US/Swiss Chamber of Commerce, after their most recent attack on the Colombia Minister of Health (MoH) announcement that a “Declaration of Public Interest” would be issued for the patents on the cancer drug imatinib, held by the Swiss company Novartis. In the US Chamber’s defense of the Swiss drug company, they don’t mention the fact that Novartis has earned about $48 billion from sales of imatinib (sold by Novartis under the brand names Gleevec or Glivec) since the drug was put on the market, including more than $380 million per month in 2015. Continue Reading
Alfred Engelberg and Aaron Kesselheim in Nature on Bayh-Dole royalty free rights in patents, Xtandi case
Alfred Engelberg and Aaron Kesselheim have published an opinion article in Nature titled:
“Use the Bayh-Dole Act to lower drug prices for government healthcare programs,” Nature Medicine 22, 576 (2016) doi:10.1038/nm0616-576, Published online 07 June 2016.
http://www.nature.com/nm/journal/v22/n6/abs/nm0616-576.html
Letter from KEI, Public Citizen, Oxfam America and Health GAP to Senator Hatch, regarding Colombia Compulsory License
Attached is a letter that KEI, Public Citizen, Oxfam America and Health GAP have sent to Senator Hatch, via the Senate Finance Committee, objecting to the pressure his office has put on Colombia over a compulsory license on patents held by Novartis for the cancer drug Gleevec. This refers to the accounts of pressure from Hatch’s office that are described in two letters from the Colombia Embassy in Washington, dated April 27 and April 28, which were recently leaked. Continue Reading
2016: MeiraGTx, NIH license of patents on AAVMediated Aquaporin Gene Transfer To Treat Sjögren’s Syndrome
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) May 16th, 2016 Sally Hu, Ph.D., M.B.A., Senior Licensing and Patenting Manager, Office of Technology Transfer and Innovation Access, National Institute of Dental and Craniofacial… Continue Reading
Fundación Karisma at WIPO SCCR32 on broadcast treaty
Good afternoon, and thank you very much, sir.
I wanted to refer to the rights to be granted in this proposed treaty and I would like to give you an example of something that has recently happened in Colombia and how sometimes the retransmission rights can be abused.
KEI comment on USTR’s 2016 Special 301 report
The 2016 USTR Special 301 report is now available. (copy here). The report is 77 pages of complaints about intellectual property policies around the world, plus a number of other complaints, including those related to pricing and reimbursement of pharmaceutical drugs and medical devices, restrictions on data flows, standard setting, and government procurement.
On the one hand, USTR says it is supports “access to medicine for all.”
2015 Oct 16 version: RCEP draft text for investment chapter
(More KEI RCEP leaks here: /rcep)
Attached below is the October 16, 2015 version of the investment chapter for the proposed Regional Comprehensive Economic Partnership, known as RCEP. This text is made public for the first time by KEI.
